Eighty female , chemotherapy-nave breast cancer patients ( median age 49 , range 24-67 years ) scheduled for four or five courses of adjuvant 3 weekly doxorubicin plus cyclophosphamide ( AC ) chemotherapy , were randomly assigned to receive 80mg PC-SOD ( human recombinant SOD bound to lecithin ) or placebo , administered intravenously ( i.v. ) immediately prior to each AC course .